CMS Takes Steps To Implement New Dx Payment System
This article was originally published in The Gray Sheet
Executive Summary
The Medicare agency issued its proposed rule to implement diagnostics provisions of the Protecting Access to Medicare Act, which would transform how lab tests are paid to a more market-based system beginning in 2017. Although laboratories support the law, an industry group says CMS would leave too many labs out from reporting market data, threatening reimbursement accuracy.
You may also be interested in...
Labs Get Extra Year To Adjust To Diagnostics Reimbursement Revamp
CMS issued a long-awaited final rule that will establish a new market-based approach to setting lab-test payment rates. The Medicare agency was convinced to delay implementation by one year, to 2018, and to make other tweaks to its policy that industry stakeholders say will make the system more accurate.
Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law
A new law makes vast changes to how clinical laboratory tests will be reimbursed by Medicare over the long term. Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.